Effectiveness of Serum Leucine-rich Alpha-2 Glycoprotein Levels on IBD
ConditionLRG Levels
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorShowa Inan General Hospital
About this trial
We attempt to examine the association between serum leucine-rich alpha-2 glycoprotein (LRG) levels and endoscopic activity in patients with possible ulcerative colitis (UC) or Crohn's disease (CD) to determine whether LRG was a predicting marker for UC or CD.
Eligibility criteria
Qualifiers
Patients whom possible UC or Crohn disease was suspected
Disqualifiers
other autoimmune diseases
acute or chronic renal failure
chronic heart diseases
liver cirrhosis
Trial design
Treatments tested in this trial
- serum leucine-rich alpha-2 glycoprotein (LRG) levels
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov